Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer

Season 4 Episode 44  ·  Mar 29, 2021, 08:00 PM

Headliner
Share
Subscribe

Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.

Share
Subscribe
Next
The Marshalls Open a Candid Conversation About Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air